Merck to Appeal Verdict in Texas VIOXX® Product Liability Case
Advertisement
Merck & Co., Inc. is disappointed a state court jury in Brazoria County, Texas, returned a verdict in favor of the plaintiff in the VIOXX® product liability lawsuit Ernst v. Merck. Merck will appeal the verdict.
"We believe that the plaintiff did not meet the standard set by Texas law to prove VIOXX caused Mr. Ernst's death," said Jonathan Skidmore of Fulbright & Jaworski, a member of Merck's defense team. "There is no reliable scientific evidence that shows VIOXX causes cardiac arrhythmias, which an autopsy showed was the cause of Mr. Ernst's death, along with coronary atherosclerosis."
"This case did not call for punitive damages," added Skidmore. "Merck acted responsibly - from researching VIOXX prior to approval in clinical trials involving almost 10,000 patients - to monitoring the medicine while it was on the market - to voluntarily withdrawing the medicine when it did."
Merck is examining various bases for appeal, including: allowing opinion testimony to be given to the jury by unqualified experts, allowing opinion testimony that was not based on a reliable scientific basis as required by Texas law, allowing evidence with no relevance to the issues of the case, which unfairly prejudiced the jury, and allowing undisclosed surprise witness and expert testimony contrary to Texas law.
"We believe that we have strong points to raise on appeal and are hopeful that the appeals process will correct the verdict," said Kenneth C. Frazier, senior vice president and general counsel of Merck. "Our appeal is about fundamental rights to a fair trial."
"There are other VIOXX cases coming to trial and we will vigorously defend them one by one over the coming years," Frazier added.
Most read news
Organizations
Other news from the department politics & laws

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Coatex SAS - Genay, France

Point of light - Caltech engineers invent light-focusing device that may lead to applications in computing, communications, and imaging
Purac and AkzoNobel develop additives for poly lactic acid
Praxair Acquires American Gas Group

Lightweight metal foams become bone hard and explosion proof after being nanocoated
DKSH and Kodak Specialty Chemicals join hands in high-value chemicals agreement
Element Six completes its acquisition of Barat Carbide Group
Methanex annouces plans to close Kitimat plant

Sales and Earnings at WACKER Defined by Lower Volumes in Q2 2024 - “Even though a sustained turnaround is not yet in sight, we are seeing the first signs that the economy is recovering...”
Flipping the switch - Physicists design quantum switches which can be activated by single photons
Scientists create world’s first ‘super-twisted’ light
